DU Zhen, CHEN Xishan, SHENG Zengmei. Clinical value of detection of cervical thin-layer cytology test and high-risk human papilloma virus in patients with cervical cancer and cervical intraepithelial neoplasia[J]. Journal of Clinical Medicine in Practice, 2020, 24(17): 24-27. DOI: 10.7619/jcmp.202017006
Citation: DU Zhen, CHEN Xishan, SHENG Zengmei. Clinical value of detection of cervical thin-layer cytology test and high-risk human papilloma virus in patients with cervical cancer and cervical intraepithelial neoplasia[J]. Journal of Clinical Medicine in Practice, 2020, 24(17): 24-27. DOI: 10.7619/jcmp.202017006

Clinical value of detection of cervical thin-layer cytology test and high-risk human papilloma virus in patients with cervical cancer and cervical intraepithelial neoplasia

More Information
  • Received Date: June 19, 2020
  • Available Online: September 29, 2020
  • Objective To investigate the clinical value of cervical thin-layer cytology test(TCT)and high-risk human papilloma virus(hrHPV)detection in patients with cervical cancer and cervical intraepithelial neoplasia. Methods Clinical therapentic conditions of 72 cervical cancer and cervical intraepithelial neoplasia patients were retrospectively analyzed. All patients performed TCT and hrHPV. The sensitivities and specificities of TCT and hrHPV detection were analyzed, and their coincidence rates with pathological results were analyzed. Results TCT results of 72 patients showed that 42 cases presented normal results, accounting for 58.3%(42/72), and 30 cases were abnormal, accounting for 41.7%(30/72). The rate of TCT detection that was in with pathological results of cervical intraepithelial neoplasia was 44.2%(19/43), the rate of TCT detection that was in with pathological results of cervical cancer was 72.7%(8/11). The hrHPV test results showed that 52 patients were positive, accounting for 72.2%(52/72), and 20 patients were negative, accounting for 27.8%(20/72). The rate of hrHPV detection accordance with pathological results was 86.0%(37/43)in diagnosis of cervical intraepithelial neoplasia and was 90.9%(10/11)by TCT in diagnosis of cervical cancer. The sensitivity and coincidence rate of TCT and hrHPV combined detection were 94.4% and 90.3% respectively, which were significantly higher than TCT or hrHPV detection alone. Conclusion TCT - and hrHPV combined detection can improve the detection rate of patients with cervical cancer and cervical intraepithelial neoplasia.
  • 胡森阳, 唐雪. 黔江区宫颈上皮内病变妇女HPV高危亚型分布关系[J]. 中国妇幼保健, 2019, 34(20): 4633-4635.
    武丽, 李兵, 吴云涛, 等. 广东省农村妇女宫颈癌前病变及宫颈癌影响因素分析[J]. 现代预防医学, 2019, 46(19): 3509-3513.
    MANGIERI L F L, SENA M M, CEZAR-DOS-SANTOS F, et al. CCR5 genetic variants and epidemiological determinants for HPV infection and cervical premalignant lesions[J]. Int J Immunogenet, 2019, 46(5): 331-338.
    GANESAN R. HPV-related cervical glandular lesions[J]. Diagn Histopathol, 2018, 24(1): 18-25.
    BASU P, TAGHAVI K, HU S Y, et al. Management of cervical premalignant lesions[J]. Curr Probl Cancer, 2018, 42(2): 129-136.
    CASTLE P E, MUROKORA D, PEREZ C, et al. Treatment of cervical intraepithelial lesions[J]. Int J Gynecol Obstet, 2017, 138: 20-25.
    曾月, 陈梦捷, 覃露, 等. 体液免疫水平与宫颈上皮内病变及早期宫颈癌的相关性[J]. 中国免疫学杂志, 2018, 34(12): 1857-1860.
    王帆, 刘荣, 瞿全新. 宫颈随机活检在宫颈高级别病变诊断中的应用[J]. 山东医药, 2019, 59(18): 70-72.
    CANFELL K. Cervical screening in HPV-vaccinated populations[J]. Climacteric, 2018, 21(3): 227-234.
    MAGED A M, SAAD H, SALAH E, et al. Urine test for HPV genotypes as a predictor of precancerous cervical lesions and for cervical cancer screening[J]. Int J Gynecol Obstet, 2018, 141(3): 332-336.
    YALCIN I, SARI M E, SAHIN H, et al. Colposcopic biopsy findings among women with either HPV-16 only or HPV-18 only who have normal cervical cytology[J]. Int J Gynaecol Obstet, 2018, 143(3): 300-305.
    WANG, YANG Y Z, DONG W W, et al. Application of human papillomavirus in screening for cervical cancer and precancerous lesions[J]. Asian Pac J Cancer Prev, 2013,14(5): 2979-2982.
    刘双玥, 张雯, 马丽莎, 等. 宫颈高级别病变和宫颈癌患者HPV感染状况及基因型分布[J]. 江苏医药, 2019, 45(7): 653-655.
    谌琼华. HPV DNA分型检测在宫颈病变及宫颈癌鉴别诊断中的价值[J]. 检验医学, 2019, 34(6): 498-501.
    向睿, 王静依, 孟侠, 等. 不同严重程度宫颈组织学病变中宫颈HPV感染检出率及HPV和TCT在宫颈病变筛查中的价值[J]. 中国妇幼保健, 2019, 34(18): 4192-4194.
    方莉, 韩瑜, 许媛, 等. 高危型HPV感染与宫颈癌前病变及宫颈癌的相关性研究[J]. 中国实验诊断学, 2019, 23(4): 602-605.
    李洋, 李永丽, 王芦萍. HPV感染型别及多重感染对宫颈病变的影响[J]. 中华医院感染学杂志, 2019, 29(22): 3461-3464

    , 3472.
    GARLAND S M, DIMECH W, COLLIGNON P, et al. The new screening program to prevent cervical cancer using HPV DNA: getting the balance right in maintaining quality[J]. J Pathol Clin Res, 2018, 4(4): 207-212.
    NASSEREDDINE H, CHARPENTIER C, BUCAU M, et al. Interest of cytology combined with Xpert HPV and Anyplex ⅡHPV28 Detection human papillomavirus(HPV)typing: differential profiles of anal and cervical HPV lesions in HIV-infected patients on antiretroviral therapy[J]. HIV Med, 2018, 19(10): 698-707.
    由月兰, 初悦美, 荆翠红, 等. TCT、高危HPV分型检测联合阴道镜检查在宫颈癌筛查中的应用价值[J]. 中国妇幼保健, 2018, 33(2): 452-454.
    KARES S, VEIJALAINEN O, KHOLOVÁI, et al. HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?[J]. APMIS, 2019, 127(11): 710-716.
    石杏先, 余立群, 高国兰. 318例高级别宫颈上皮内瘤变及宫颈癌患者的TCT和hrHPV检测分析[J]. 中国肿瘤临床, 2019, 46(2): 73-76.
    赵培玉, 陈敖峥, 秦锦龙, 等. CervistaHR-HPVDNA检测联合TCT在宫颈癌筛查中的临床价值[J]. 检验医学, 2017, 32(4): 322-325.
    杨国红, 陆欢. HPV-DNA与TCT检测在宫颈上皮内瘤变筛查中的效果分析[J]. 中国妇幼保健, 2019, 34(23): 5406-5408.
    TIFAOUI N, MAUDELONDE T, COMBECAL J, et al. High-risk HPV detection and associated cervical lesions in a population of French menopausal women[J]. J Clin Virol, 2018, 108: 12-18.
  • Related Articles

    [1]ZHOU Yangfan, YANG Xiaoyang, ZHU Chengquan, WANG Aiwu, CHEN Yanyu, TAN Xi, CHEN Yu, ZE Haocheng, LIU Yanhong. Value of thinprep cytologic test combined with detection of high-risk human papillomavirus in screening of cervical cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(15): 46-50,54. DOI: 10.7619/jcmp.202015013
    [2]ZHENG Jianjun. Value on detection of high-risk human papilloma virus, squamous cell carcinoma antigen and squamous cell associated carcinoma antigen after radical resection of cervical cancer[J]. Journal of Clinical Medicine in Practice, 2019, 23(23): 58-60. DOI: 10.7619/jcmp.201923017
    [3]FENG Lanlan, SUN Youhong, XIA Aihua, LI Haiyan. Agreement rate of grade 1 cervical intraepithelial neoplasia diagnosed by colposcopic cervical biopsy with pathological results and high risk factors of pathological upgrading[J]. Journal of Clinical Medicine in Practice, 2019, 23(22): 88-90. DOI: 10.7619/jcmp.201922030
    [4]LI Juan, LIU Yuehong, GU Ping, ZHU Mengtian, MA Xiaoling, LIU Yinmei. Significance of screening cervical lesionsby cytology examination combined with human papilloma virus genotyping[J]. Journal of Clinical Medicine in Practice, 2019, 23(14): 72-75. DOI: 10.7619/jcmp.201914019
    [5]LI Rui, LIU Li′na, CHEN Lida. Effect of 5-aminolaevulinic acid-based photodynamictherapy for cervical HPV infection patients with cervical intraepithelial neoplasia[J]. Journal of Clinical Medicine in Practice, 2019, 23(11): 63-65, 69. DOI: 10.7619/jcmp.201911018
    [6]XIE Songgang, ZHANG Ling. Analysis on the results of 4 682 females with high-risk human papillomavirus infection in Yangzhou[J]. Journal of Clinical Medicine in Practice, 2019, 23(8): 88-91. DOI: 10.7619/jcmp.201908025
    [7]HU Quan. Epidemiological investigation on patients with cervical high-risk human papilloma virus infection[J]. Journal of Clinical Medicine in Practice, 2018, (17): 65-67. DOI: 10.7619/jcmp.201817018
    [8]WU Bo. Expression of p16INK4A protein in cervical adenocarcinoma patients with high-risk human papilloma virus[J]. Journal of Clinical Medicine in Practice, 2016, (5): 100-102. DOI: 10.7619/jcmp.201605030
    [9]LIU Xiaoyun, PENG Hudan. Application of human papillomavirus DNA combined with thinprep cytologic test in the diagnosis of cervical lesions[J]. Journal of Clinical Medicine in Practice, 2016, (3): 91-94. DOI: 10.7619/jcmp.201603028
    [10]LIU Hanzhong, YANG Jizhou, XIAO Lan, LU Ye, DAI Yifei, WANG Lan. Liquid-based cytology combined HPV-DNA genotyping in cervical cancer screening[J]. Journal of Clinical Medicine in Practice, 2013, (9): 44-46,49. DOI: 10.7619/jcmp.201309013
  • Cited by

    Periodical cited type(17)

    1. 杨志国. 微创拔牙术治疗下颌低位阻生智齿的有效性及作用研究. 罕少疾病杂志. 2025(03): 40-42 .
    2. 金苏菊,李雪晶,刘凤林,朱晓洁. 规范化循证护理干预联合四手操作配合在下颌水平低位阻生智齿拔除术中的应用. 齐鲁护理杂志. 2024(06): 152-154 .
    3. 周芳,曾文玲. 循证护理联合规范化疼痛护理在低位阻生智齿拔除中的应用效果. 医疗装备. 2024(06): 123-125 .
    4. 吴康,王国栋. 微创拔牙术拔除下颌低位阻生智齿对疼痛程度的影响. 中国卫生标准管理. 2024(09): 123-127 .
    5. 方首镕,王晓云,雷雨露,宁润来,蒋宁宁. 下颌低位阻生智齿拔除应用CBCT介导超声骨刀的效果及对PTX3、MPO、PGE2的影响. 中国医学工程. 2023(02): 59-63 .
    6. 潘其达. 不翻瓣法配合涡轮机拔除下颌阻生智齿的应用效果及预后观察. 现代诊断与治疗. 2023(03): 428-430 .
    7. 王鑫,侍泉华. 浓缩生长因子在下颌阻生齿拔除术中的应用效果及对患者生活质量的影响. 中国美容医学. 2023(05): 142-145 .
    8. 王军,刘素芳,王会敏. 微创拔牙术治疗下颌复杂阻生牙的临床疗效. 深圳中西医结合杂志. 2023(08): 115-118 .
    9. 许慧英. 微创拔牙术在下颌阻生智齿拔除治疗中的应用及对患者拔牙后张口受限程度以及并发症情况的影响. 系统医学. 2023(08): 169-173 .
    10. 徐金伟,张琴,陈海苏,于保军,俞辉明. 高速涡轮钻联合超声骨刀对下颌低位阻生智齿拔除的效果. 中国医药导报. 2023(21): 129-132 .
    11. 杨剑. 微创拔牙器械配合高速涡轮牙钻拔牙法在下颌低位阻生智齿治疗中的效果评价. 中国医药科学. 2023(13): 195-198 .
    12. 邹雅琴,凌瑞,劳茉,王敬雯,栗璞. 微创拔牙术在下颌阻生智齿拔除中的应用价值. 实用临床医学. 2023(03): 74-77 .
    13. 张莉,闫召民,姚燕,王宇. 高速涡轮机联合微创拔牙刀在下颌阻生智齿中的应用及对疼痛程度、并发症的影响分析. 黑龙江医学. 2023(19): 2313-2315 .
    14. 王笑梅. 高速涡轮牙钻联合微创拔牙刀在阻生智齿拔除术中的应用效果. 医学信息. 2023(21): 118-121 .
    15. 沈博文. 微创拔牙与传统器械拔牙治疗下颌阻生智齿的疗效对比分析. 现代医学与健康研究电子杂志. 2022(03): 7-9 .
    16. 孙辉,陈志方,王晓东. 下颌水平低位阻生齿拔除术治疗下颌阻生第三磨牙对患者牙周健康状况的影响. 湖南师范大学学报(医学版). 2022(04): 74-77 .
    17. 杜文斌,曹玮奇,姚国华,张帅,李尔涛,任辉. 十字形分牙法在下颌水平低位阻生齿拔除中的临床效果分析. 中国美容医学. 2021(12): 105-108 .

    Other cited types(0)

Catalog

    Article views (334) PDF downloads (7) Cited by(17)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return